ASH In Review: Roche Refreshes Hematology Portfolio With Robust New Drugs
Executive Summary
Phase II data for antibody-drug conjugate polatuzumab vedotin in diffuse large B cell lymphoma suggest potential for a cure if the drug were given up front, Roche says on investor call after American Society of Hematology meeting.
You may also be interested in...
CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy
In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.
CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy
In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.
AbbVie, J&J's Imbruvica Has Rare, But Not Surprising Failure In DLBCL
Analysts generally were not surprised that Imbruvica plus R-CHOP did not provide a significant benefit versus R-CHOP alone in a hard-to-treat type of non-Hodgkin lymphoma. The failure leaves an opening for competitors, such as Celgene's Revlimid, which will soon have data in this indication.